Boehringer Ingelheim Licenses Noval Oral Therapeutics Program from Sitryx

Boehringer Ingelheim has acquired an exclusive license for a preclinical, small molecule program from Sitryx Therapeutics, a clinical-stage biopharmaceutical company. The program offers a novel, oral, potentially disease-modifying treatment approach across multiple autoimmune and inflammatory disease indications.

Under the terms of the agreement, Sitryx grants Boehringer an exclusive global license to the multiple candidates and associated intellectual property within this small molecule inhibitor program. Boehringer assumes full responsibility for the program, including further research, clinical development and commercialization. Sitryx receives both upfront and near-term payments and is eligible to receive potential development, regulatory and commercialization milestone payments totaling more than $500 million, in addition to tiered royalties on future sales.

“Autoimmune and inflammatory diseases remain areas where innovation is urgently needed. Sitryx’s small molecule inhibitor program brings forward a promising new mechanism that aligns with our focus on advancing first-in-class approaches,” said Carine Boustany, Head of Immunology and Respiratory Diseases Research at Boehringer Ingelheim. “Together with Sitryx, we are committed to translating this science into therapies that can meaningfully improve patients’ lives.”

“This collaboration is a major milestone for our company and is a clear validation of the strength of our pipeline and our expertise translating immunometabolic targets into meaningful therapeutic candidates,” said Iain Kilty, CEO of Sitryx. “We are proud to out-license this preclinical program to Boehringer Ingelheim whose global capabilities in immunology and drug development will help position this program to deliver meaningful benefits to patients worldwide.”